Repros Reports Financing Of $1.0m

Repros Therapeutics (Repros) has entered into an agreement with a single institutional investor to sell 1.5 million shares of its common stock at $0.65 per share for gross proceeds of approximately $1.0m.

Reportedly, the financing will allow Repros to continue its business activity for the near term and provide it with more flexibility to continue exploring various strategic alternatives. The offering is expected to close on or about September 11, 2009, subject to the satisfaction of customary closing conditions.

Repros, a development stage biopharmaceutical company focused on the development of oral small molecule drugs to address major unmet medical needs in male and female health.